GoX Studio Introduces GoX Ergo, Wearable Sensors to Improve Worker Wellness and Safety

April 24, 2018 11:13 AM

GoX Ergo is the Only Sensor Kit on the Market That Measures Form, Fatigue, Force, and Rate of Perceived Exertion from the User. PHOENIX, AZ / ACCESSWIRE / April 24, 2018 / Wearable sensors and innovative algorithms are now able to protect factory workers from bad lifts and overexertion that increase the risk of injury. GoX Studio, an innovator in worker assessment using proprietary wearable sensors and algorithms, has developed the most...

Read more

MorphoSys Announces Closing of Nasdaq IPO through an ADS Offering and Exercise of the Underwriters' Option to Purchase Additional ADSs, Leading to Total Gross Proceeds of USD 239 million

April 23, 2018 4:20 PM

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / April 23, 2018 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC PINK: MPSYY; NASDAQ: MOR) announced today the closing of its initial public offering (IPO) in the United States. The offering comprised the sale of 2,075,000 new ordinary shares in the form of 8,300,000 American Depositary Shares ("ADSs") at a price of USD 25.04 per ADS. Each ADS represents 1/4 of a MorphoSys ordinary share. In...

Read more

GoX Studio Partners with Briotix to Improve Worker Wellness Using Wearable Sensors

April 23, 2018 1:50 PM

Ergonomists' Dreams Are Fulfilled by GoX Ergo, the Only Sensor Kit on the Market That Measures Form, Fatigue, Force, and Rate of Perceived Exertion from the User PHOENIX, AZ / ACCESSWIRE / April 23, 2018 / GoX Studio is pleased to announce a partnership with Briotix to bring state-of-the-art injury prevention to industrial workers by providing elite teams of Briotix ergonomists GoX Ergo kits. Wearable sensors in each GoX Ergo kit provide over 20...

Read more

Anergis and Mymetics Start Research Collaboration Project on the use of Virosomes for Ultra-Fast Allergy Immunotherapy

April 23, 2018 2:00 AM

EPALINGES, SWITZERLAND / ACCESSWIRE / April 23, 2018 / Mymetics Corporation (OTCQB:MYMX), a pioneer and leader in the research and development of virosome-based vaccines, and Anergis SA, a company developing Contiguous Overlapping Peptides (COPs) for ultra-fast allergy immunotherapy, announced today that Mymetics SA, the Swiss subsidiary of Mymetics Corporation and Anergis SA have entered into a Research Collaboration project. The pre-clinical...

Read more

Molecular Partners Presented Preliminary Results from the Ongoing Phase 2 Study of MP0250 at the European Myeloma Network Meeting in Turin

April 21, 2018 4:15 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / April 21, 2018 / Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, announced today that preliminary results from the ongoing Phase 2 study of MP0250 with bortezomib and dexamethasone in patients with relapsed refractory multiple myeloma (RRMM) were presented at the 1st European Myeloma Network Meeting in...

Read more

Professor Chenfeng Ke of Dartmouth College Joins Qrons Scientific Advisory Board

April 20, 2018 9:35 AM

MIAMI, FL / ACCESSWIRE / April 20, 2018 / Qrons Inc. (OTC PINK: QRON) ("Qrons" or the "Company") a preclinical biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries ("TBIs") is pleased to announce that Chenfeng Ke, Assistant Professor of Chemistry at Dartmouth College has joined its Scientific Advisory Board. Professor Ke and his group focus on syntheses and...

Read more

MorphoSys Announces Pricing of Initial Public Offering of American Depositary Shares (ADSs) on Nasdaq

April 18, 2018 5:45 PM

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / April 18, 2018 / MorphoSys AG (FSE: MOR; XETRA: MOR ; Prime Standard Segment, TecDAX; OTC PINK: MPSYY) announced today the pricing of its initial public offering (IPO) in the United States. The offering produced gross proceeds of USD 207,832,000 from the sale of 2,075,000 new ordinary shares in the form of 8,300,000 American Depositary Shares ("ADSs") at a price of USD 25.04 per ADS. Each ADS will...

Read more

Shareholders of Molecular Partners AG Approve All Board Proposals at the Annual General Meeting - Bill Burns Elected New Chairman

April 18, 2018 11:29 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / April 18, 2018 / At today's Annual General Meeting of Molecular Partners AG (SIX: MOLN), the shareholders of the company approved all motions proposed by the Board of Directors with a large majority and elected William (Bill) Burns as new Chairman of the Board. At today's Annual General Meeting of Molecular Partners AG, Bill Burns was elected new Chairman of the Board of the company. Bill held various...

Read more

AYOXXA Launches LUNARIS(TM) Human 12-Plex Th17 Kit Expanding Its Portfolio For Fully Scalable Biomarker Analysis

April 18, 2018 3:44 AM

LUNARISTM Th17 Cell Biology Kits for the quantitative analysis of highly specific soluble pro-inflammatory Th17 cell markers in translational research In combination with the LUNARISTM Mouse 12-Plex Th17 Kit, the new product allows researchers to conduct comparative studies of Th17 cell activation and its effects on immune-mediated diseases from model to man without changing platforms Launch marks a further step in...

Read more

MorphoSys Resolves a Capital Increase to Implement the Offering of 8,300,000 American Depositary Shares (ADS) in the United States

April 17, 2018 7:40 PM

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / April 17, 2018 / MorphoSys AG (XETRA: MOR; FSE: MOR; Prime Standard Segment, TecDAX; OTC PINK: MPSYY) announced today that its Management Board, with the approval of the Supervisory Board, has resolved to increase the share capital of MorphoSys AG by issuing 2,075,000 new ordinary shares from the authorized capital 2017-II, excluding pre-emptive rights of existing shareholders, to implement the initial...

Read more

NeurOp Initiates Phase 1 Clinical Trial of NMDA Receptor Inhibitor NP10679

April 12, 2018 10:25 AM

ATLANTA, GA / ACCESSWIRE / April 12, 2018 / NeurOp, Inc., a clinical-stage biotechnology company, today announced the initiation of a Phase 1 clinical trial of NP10679, a highly potent and selective GluN2B subunit-specific NMDA (N-methyl-D-aspartate) receptor inhibitor. NeurOp is investigating NP10679 for several neurological disorders that are associated with over-activity of these receptors. The randomized, placebo-controlled, single ascending...

Read more

Molecular Partners and AstraZeneca Announce Collaboration on Molecular Partners’ Ongoing Oncology Clinical Study With MP0250 in EGFR-Mutated NSCLC

April 11, 2018 1:00 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / April 11, 2018 / Molecular Partners AG (SWX: MOLN), a clinical-stage biopharmaceutical company that is developing a new class of drugs, known as DARPin® therapies*, announced today that Molecular Partners and AstraZeneca (LON: AZN) will collaborate on Molecular Partners' ongoing phase 1b/2 clinical study of MP0250 with osimertinib (Tagrisso®) for the treatment of patients with EGFR-mutated...

Read more

MorphoSys Nominates New Candidates for Supervisory Board

April 10, 2018 10:25 AM

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / April 10, 2018 / MorphoSys AG (FSE: MOR) (XETRA: MOR) (OTC PINK: MPSYY) announced today that it has published its agenda for the Company's ordinary Annual General Meeting (AGM), which will take place on Thursday, May 17, 2018. MorphoSys's Supervisory Board has nominated Dr. George Golumbeski and Michael Brosnan as candidates to be elected as new Supervisory Board members at the Company's AGM. Dr. Gerald...

Read more

Ad hoc: MorphoSys Announces Launch of American Depositary Shares (ADS) Offering in the United States

April 9, 2018 7:50 AM

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / April 9, 2018 / MorphoSys AG (FSE: MOR) (XETRA: MOR) (OTC PINK: MPSYY) announced today that it has commenced an initial public offering in the United States of up to 8,300,000 American Depositary Shares ("ADSs") pursuant to a Registration Statement on Form F-1, as amended, filed with the U.S. Securities and Exchange Commission. Furthermore, MorphoSys expects to grant the underwriters a 30-day option to...

Read more

MorphoSys Announces Approval of Tremfya(R) (Guselkumab) for the Treatment of Moderate to Severe Forms of Psoriasis and Psoriatic Arthritis in Japan

April 6, 2018 2:17 AM

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / April 6, 2018 / MorphoSys AG (FSE: MOR) (XETRA: MOR) (OTC PINK: MPSYY) announced today that its licensee Janssen Pharmaceutical K.K. (Janssen) reported that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Tremfya(R) (guselkumab) for the treatment of three forms of psoriasis (plaque, pustular, and erythrodermic) and psoriatic arthritis in patients with moderate-to-severe disease for whom...

Read more

MorphoSys Announces Approvals for Tremfya(R) (Guselkumab) for the Treatment of Moderate-to-Severe Plaque Psoriasis in Brazil and Australia

April 5, 2018 10:30 AM

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / April 5, 2018 / MorphoSys AG (FSE: MOR) (XETRA: MOR) (OTC PINK: MPSYY) announced today that country subsidiaries of its licensee Janssen reported that Tremfya(R) (guselkumab) has been approved for the treatment of adults living with moderate to severe plaque psoriasis in Brazil and Australia. As reported by Janssen-Cilag Farmacêutica Ltda. (Janssen), the Brazilian National Health Surveillance Agency...

Read more

Molecular Partners to Present MP0310 Pre-clinical Data and MP0250 Clinical Abstracts at the AACR Annual Meeting 2018

April 5, 2018 1:00 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / April 5, 2018 / Molecular Partners AG (SWX: MOLN), a clinical-stage biopharmaceutical company that is developing a new class of drugs, known as DARPin® therapies, today announced that new pre-clinical data from two of its pipeline candidates, MP0310 and its lead proprietary oncology drug MP0250, as well as the DARPin® toolbox will be presented at the Annual Meeting 2018 of the American...

Read more

Pressure BioSciences, Inc. to Discuss Fourth Quarter and FY2017 Financial Results and Provide Business Update

March 29, 2018 8:16 AM

SOUTH EASTON, MA / ACCESSWIRE / March 29, 2018 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its Fourth Quarter and Fiscal Year 2017 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay (by telephone or via a link on the Company's website approximately one...

Read more

ZIVO Bioscience, Inc. Welcomes New Vice-President of Research & Development

March 29, 2018 8:00 AM

KEEGO HARBOR, MI / ACCESSWIRE / March 29, 2018 / ZIVO Bioscience, Inc. (OTCQB: ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional and medicinal products derived from proprietary algal strains, announces today William P. Pfund has joined the Company as its new Vice-President of Research & Development. Mr. Pfund will manage overall research objectives, compliance initiatives and help transition the Company's...

Read more

Cryo Announces Notice of Allowance of Claims for Its Core Patent

March 27, 2018 6:00 AM

EATONTOWN, NJ / ACCESSWIRE / March 27, 2018 / American CryoStem Corporation (OTC PINK: CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced receiving a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. patent application 13/702.304 related to methods of Collection, Processing,...

Read more